Breaking: WHO Declares Bundibugyo Virus (BDBV) a Public Health Emergency of International Concern (PHEIC)

On May 16, the WHO Director-General declared that the Bundibugyo virus disease (BVD) outbreak affecting the Democratic Republic of the Congo (DRC) and Uganda constitutes a Public Health Emergency of International Concern (PHEIC). This marks the DRC's 17th Ebola outbreak, with 500 suspected cases and 130 deaths (including confirmed fatalities) reported to date, alongside imported cases identified in Uganda. Unlike Zaire ebolavirus (EBOV), no approved vaccines or specific therapeutics currently exist for BDBV, and diagnostic capacity remains largely confined to specialized reference laboratories — severely limiting the ability to assess the true scale of the outbreak.

Bundibugyo virus (BDBV) is a member of the genus Ebolavirus within the family Filoviridae. First isolated in Bundibugyo District, Uganda in 2007, it is the third known ebolavirus species to cause large-scale human disease, following the discovery of Zaire ebolavirus (EBOV) and Sudan virus (SUDV) in 1976. At the genomic level, BDBV diverges substantially from EBOV, sharing only approximately 58–61% nucleotide sequence identity. Historical epidemiological data from the two major BDBV outbreaks — Uganda in 2007 and the DRC in 2012 — recorded case fatality rates ranging from 30% to 50%.

Figure 1. Health zones in the Democratic Republic of the Congo affected by Bundibugyo virus disease as of May 16, 2026.

(Source: WHO official website）

The BDBV genome is a single-stranded, negative-sense RNA (ssRNA⁻) approximately 18,940 nucleotides in length — consistent with the typical 18.9–19 kb range of the genus. It encodes seven major structural proteins in the following order: NP, VP35, VP40, GP, VP30, VP24, and L. These proteins act in concert to drive viral replication, particle assembly, and evasion of host immune defenses. Viral particles display the characteristic filamentous or thread-like morphology of filoviruses, with a uniform diameter of approximately 80 nm and lengths reaching up to 14 μm. Particles can adopt branched, U-shaped, "6"-shaped, or circular conformations, and are enclosed by a lipid envelope studded with GP glycoprotein spikes.

Figure 2. Virion and genome structure of EBOV.

（Source: https://doi.org/10.1016/j.jobb.2023.05.001)

Key Structural Proteins and Their Functions

Pathogenesis

Within 1–3 days of exposure, BDBV enters the body through mucosal surfaces or skin abrasions and undergoes rapid replication in dendritic cells and monocytes, before disseminating to hepatocytes, endothelial cells, and epithelial cells. Between days 3 and 14, systemic viral spread, dysregulated host immune responses, coagulopathy, vascular injury, and hypotension converge to precipitate shock and multi-organ failure. Overexpression of tissue factor (TF) in monocytes and macrophages is a pivotal event that triggers the hemorrhagic complications characteristic of BDBV infection: TF transcript levels rise by day 3, TF protein surges by day 2, and large quantities of TF-expressing membrane microparticles are detectable in plasma. Intense viral replication in the liver leads to marked hepatocellular necrosis and severe hepatic injury; the resulting impairment of coagulation factor synthesis drives the coagulopathy that is one of the defining pathological hallmarks of Ebola virus disease (EVD).

Figure 3. Model of Ebola virus disease pathogenesis.

(Source: doi:10.1016/S0140-6736(10)60667-8)

Recent Research Advances

To date, no approved vaccines or specific therapeutics exist for Bundibugyo virus (BDBV). Existing countermeasures developed against Zaire ebolavirus (EBOV) — including Ervebo (rVSV-ZEBOV), Inmazeb (REGN-EB3), and Ebanga (mAb114) — offer limited or no cross-protection against BDBV. Clinical management therefore relies heavily on supportive care, including fluid resuscitation, electrolyte management, organ support, and symptom control, all of which significantly reduce mortality when implemented promptly. Rapid RT-PCR diagnostics and whole-genome sequencing remain the cornerstone of outbreak surveillance. Research efforts are concentrated on the GP glycoprotein, particularly its conserved regions, and on the development of pan-ebolavirus vaccine platforms and antibody combinations.

Figure 4. Development stages of Ebola virus vaccines in the United States.

(Source: https://doi.org/10.1038/s41541-024-00985-y)

1. The Most Promising BDBV Vaccine Candidate: The VSV-BDBV Platform

The rVSVΔG/BDBV-GP vaccine — a recombinant vesicular stomatitis virus-based construct — has demonstrated post-exposure protection against BDBV challenge. In a cynomolgus macaque model, animals vaccinated as late as 20–23 minutes after BDBV infection showed a survival rate of 5 out of 6 (83%), compared to an expected natural survival rate of only 21% in this model — a striking therapeutic effect. Separately, a single dose of rVSV-EBOV confers 100% protection in non-human primates and approximately 50% protection even when administered within 24 hours of EBOV challenge. In surviving animals, the liver and spleen showed no significant pathological lesions, whereas fatal cases exhibited necrotizing hepatitis and widespread viral antigen-positive infiltration. Although VSV-BDBV remains in preclinical testing with no human trials initiated, the animal data provide a compelling rationale for accelerated clinical development.

Figure 5. Survival outcomes and viral load comparisons in cynomolgus macaques following BDBV infection and rVSVΔG/BDBV-GP post-exposure treatment.

(Source: https://doi.org/10.1093/infdis/jiad207)

2. Multivalent Filovirus Vaccine Platforms

Beyond the VSV backbone, multivalent vaccine platforms based on adenovirus serotype 26 and modified vaccinia Ankara (Ad26-filo/MVA-BN-filo) have demonstrated protection against Sudan virus and Marburg virus in non-human primate studies. The multivalent design principles underpinning these platforms are directly extendable to provide coverage against BDBV. The key advantage of this approach is the ability to simultaneously confer broad protection across multiple filovirus species, reducing the complexity and cost of developing pathogen-specific countermeasures.

Figure 6. Immunogenicity of heterologous trivalent vaccine regimens (Ad26-Ad35, Ad26-MVA-BN-Filo, or MVA-BN-Filo-Ad26) versus Ad26-Ad35 monovalent vaccine and protection against EBOV Kikwit challenge.

(Source: https://doi.org/10.1371/journal.pone.0192312)

3. A High-Value Drug Target: The NP–VP35 Interaction Interface

Crystal structure analysis of the Sudan ebolavirus (SUDV) NP–VP35 complex has revealed a previously uncharacterized interaction interface defined by a precisely formed β-sheet. Affinity binding studies confirm that this β-sheet is essential for maintaining high-affinity interaction between VP35 and the hydrophobic pocket of NP. Electron microscopy further demonstrates that this binding interface is critical for NP oligomerization and assembly within human cells. Structure-guided mutagenesis has identified key residues conserved across the filovirus family — residues that represent ideal targets for pan-filovirus antiviral drug development.

Figure 7. Crystal structure of the SUDV VP35–NP core complex.

(Source: https://doi.org/10.1128/mBio.00734-19)

4. Multi-Target Drug Development: VP40 and VP35

Natural products isolated from myxobacteria — including Cystobactamid 919-1, Cystobactamid 934-2, and 2-Hydroxysorangiadenosine — have shown stable binding interactions with both VP35 and VP40 in molecular docking studies. Molecular dynamics simulations further confirm the stability of the Cystobactamid 919-1–VP35 and 2-Hydroxysorangiadenosine–VP40 complexes, supporting the therapeutic potential of these natural scaffolds.

Figure 8. Proposed mechanisms by which myxobacterial natural products inhibit EBOV.

(Source: https://doi.org/10.3390/biom14060660)

As the primary driver of viral assembly, VP40 is an attractive target: blocking its interaction with nuclear envelope proteins disrupts budding and the release of new virions. Inhibiting the interferon-antagonistic activity of VP35, in turn, restores innate immune signaling, enhancing viral clearance. The layered, multi-target approach targeting both proteins substantially increases the probability of therapeutic success.

Figure 9. Identification of potential Ebola virus VP35 and VP40 inhibitors from myxobacterial natural products.

(Source: https://doi.org/10.3390/biom14060660)

5. GP as a Pan-Filovirus Vaccine Antigen

BDBV GP is the primary antigen for all current vaccine strategies. Compared to EBOV, BDBV GP may adopt a distinct upstream receptor-binding domain conformation, offering opportunities for strain-specific vaccine design. The highly conserved NPC1-binding site provides a structural basis for developing broadly neutralizing monoclonal antibodies capable of cross-neutralizing multiple ebolavirus species — assets of particular value for emergency prophylactic and therapeutic interventions.

Figure 10. Monoclonal antibodies targeting the conserved GP1 receptor-binding site exhibit pan-filovirus neutralizing activity.

（Source: doi:10.1128/mBio.02154-15)

Public Health Implications

The ongoing transmission of BDBV in the DRC and Uganda underscores the urgent need for a comprehensive pan-filovirus defense framework. Priority actions include: stockpiling multivalent vaccines and treatment regimens active against BDBV, Sudan virus, and Marburg virus; building decentralized regional diagnostic capacity to eliminate dependence on single reference laboratories; advancing multinational research collaborations to accelerate vaccine and drug development; deepening environmental surveillance and studies of animal reservoir hosts; and establishing pre-negotiated emergency vaccine deployment protocols between WHO and national governments. Central to all of these efforts is a deepened understanding of filovirus molecular biology — including the structure, interactions, and immunological targets of key viral proteins.

abinScience Products for Filovirus Research

abinScience offers a comprehensive portfolio of high-quality recombinant proteins and antibodies to support filovirus research at every stage. Our catalog includes recombinant nucleoproteins (NP), polymerase cofactors (VP35), matrix proteins (VP40), and glycoproteins (GP) from BDBV, EBOV, Sudan virus, and related species, as well as species- and pan-ebolavirus-specific monoclonal and polyclonal antibodies targeting each of these key antigens. Whether your work focuses on vaccine immunogenicity assessment, diagnostic reagent development, or the screening and characterization of therapeutic antibodies, our products are designed to support your research and translational needs. Click any catalog number below to access the full product details.

References

1. Hong-Qing Zhang, Qiu-Yan Zhang, Zhi-Ming Yuan, Bo Zhang. The potential epidemic threat of Ebola virus and the development of a preventive vaccine. Journal of Biosafety and Biosecurity. 2023;5(2):67–78. doi: 10.1016/j.jobb.2023.05.001
2. Hayat M, Gao T, Cao Y, Rafiq M, Zhuo L, Li Y-Z. Identification of Prospective Ebola Virus VP35 and VP40 Protein Inhibitors from Myxobacterial Natural Products. Biomolecules. 2024;14:660. doi: 10.3390/biom14060660
3. Woolsey C, Strampe J, Fenton KA, et al. A Recombinant Vesicular Stomatitis Virus-Based Vaccine Provides Postexposure Protection Against Bundibugyo Ebolavirus Infection. J Infect Dis. 2023;228(Suppl 7):S712–S720. doi: 10.1093/infdis/jiad207. PMID: 37290053; PMCID: PMC10651203.
4. Anderson EM, Coller B-AG. Translational success of fundamental virology: a VSV-vectored Ebola vaccine. J Virol. 2024;98(3):e0162723. doi: 10.1128/jvi.01627-23. PMID: 38305150; PMCID: PMC10994820.
5. Landeras-Bueno S, Oda SI, Norris MJ, et al. Sudan Ebolavirus VP35-NP Crystal Structure Reveals a Potential Target for Pan-Filovirus Treatment. mBio. 2019;10(4):e00734-19. doi: 10.1128/mBio.00734-19. PMID: 31337716; PMCID: PMC6650547.
6. Geisbert TW, Young HA, Jahrling PB, et al. Mechanisms underlying coagulation abnormalities in ebola hemorrhagic fever: overexpression of tissue factor in primate monocytes/macrophages is a key event. J Infect Dis. 2003;188(11):1618–1629. doi: 10.1086/379724. PMID: 14639531.
7. Feldmann H, Geisbert TW. Ebola haemorrhagic fever. Lancet. 2011;377(9768):849–862. doi: 10.1016/S0140-6736(10)60667-8. PMID: 21084112; PMCID: PMC3406178.
8. Gilchuk P, Murin CD, Cross RW, et al. Pan-ebolavirus protective therapy by two multifunctional human antibodies. Cell. 2021;184(22):5593–5607.e18. doi: 10.1016/j.cell.2021.09.035. PMID: 34715022; PMCID: PMC8716180.
9. Callendret B, Vellinga J, Wunderlich K, et al. A prophylactic multivalent vaccine against different filovirus species is immunogenic and provides protection from lethal infections with Ebolavirus and Marburgvirus species in non-human primates. PLoS One. 2018;13(2):e0192312. doi: 10.1371/journal.pone.0192312. PMID: 29462200; PMCID: PMC5819775.
10. King LB, West BR, Moyer CL, et al. Cross-reactive neutralizing human survivor monoclonal antibody BDBV223 targets the ebolavirus stalk. Nat Commun. 2019;10(1):1788. doi: 10.1038/s41467-019-09732-7. PMID: 30996276; PMCID: PMC6470140.
11. Marzi A, Feldmann H. Filovirus vaccines as a response paradigm for emerging infectious diseases. NPJ Vaccines. 2024;9(1):186. doi: 10.1038/s41541-024-00985-y. PMID: 39394249; PMCID: PMC11470150.
12. Lewis CE, Pinette MM, Lakin SM, et al. Experimental Infection of Bundibugyo Virus in Domestic Swine Leads to Viral Shedding with Evidence of Intraspecies Transmission. Transbound Emerg Dis. 2024;2024:5350769. doi: 10.1155/2024/5350769. PMID: 40303058; PMCID: PMC12017203.
13. Bornholdt ZA, Ndungo E, Fusco ML, Bale S, Flyak AI, Crowe JE Jr, Chandran K, Saphire EO. Host-Primed Ebola Virus GP Exposes a Hydrophobic NPC1 Receptor-Binding Pocket, Revealing a Target for Broadly Neutralizing Antibodies. mBio. 2016 Feb 23;7(1):e02154-15. doi: 10.1128/mBio.02154-15. PMID: 26908579; PMCID: PMC4791852.